| Literature DB >> 30533279 |
Shoupeng Cao1, Loai K E A Abdelmohsen1, Jingxin Shao1, Joep van den Dikkenberg2, Enrico Mastrobattista2, David S Williams3, Jan C M van Hest1.
Abstract
Herein we describe biodegradable nanovectors comprised of block copolymers of poly(ethylene glycol) and poly(trimethylene carbonate) (PEG-PTMC) that change their morphology and surface charge when exposed to tumor environment conditions. Well-defined, drug-loaded nanovectors were prepared via direct hydration using liquid oligo(ethylene glycol) as a dispersant. Systematic introduction of basic imidazole-functional TMC derivatives, through modular polymerization, resulted in polymers that self-assembled in multilamellar nanoparticles (at neutral pH) and that were loaded with hydrophobic drugs. The resultant multilamellar nanovectors demonstrated a significant size reduction and charge reversal at pH ≈ 6.5, which yielded cationic nanovectors that were tailored for tumor penetration. In vitro studies using 3D heterospheroids demonstrate that this platform has excellent potential to promote enhanced tumor penetration under physiological conditions.Entities:
Year: 2018 PMID: 30533279 PMCID: PMC6281313 DOI: 10.1021/acsmacrolett.8b00807
Source DB: PubMed Journal: ACS Macro Lett Impact factor: 6.903
Figure 1Schematic illustrating (a) the chemical structure of PEG-TMCI-TMC terpolymers and the chemical change that occurs through protonation of imidazole moieties at low pH, (b) fabrication of drug-loaded multilamellar nanovectors (MLNs) via direct hydration and the structural reconfiguration that occurs at low pH into cationic nanovectors (CNs), and (c) the anticipated mode of action of MLNs invivo whereby local pH reduction in the TME leads to enhanced internalization of CNs and tumor penetration.
Figure 2pH-induced transformation of multilamellar nanovectors (MLNs) into cationic nanovectors (CNs) comprising PEG22-TMCI7-TMC30 terpolymers. TEM images of (a) MLNs and (b) CNs after reduction in pH (scale bars = 100 nm). AF4 fractogram (scattering profile in black) of (c) MLNs at pH 7.4 and (d) after transformation to CNs at pH 5 comparing the radius of gyration (Rg, blue) to the hydrodynamic radius (Rh, red). (e) Real-time monitoring of the pH-induced transformation of MLNs by DLS. (f) Zeta-potential measurements of MLNs/CNs at varying pH.
Figure 3MLN performance in vitro. (a) Fluorescent images of HepG2 cells treated with Ce6-labeled MLNs for 2 h at pH 7.4 and 6.5 (scale bar = 20 μm). (b) Flow cytometry results for uptake into HepG2 cells at pH 7.4 (gray) and 6.5 (red) compared to control cells (light gray).
Figure 4MLN performance in vitro. Cell viability of (a) HeLa and (b) HepG2 cells after treatment with free cisplatin prodrug (blue) and drug-loaded MLNs at pH 7.4 (black) and 6.5 (red).
Figure 5MLN performance in vitro. (a) Fluorescent images following penetration into 3D MCSs at pH 7.4 and 6.5 (scale bar = 200 μm). (b) Quantification of fluorescent data in (c) after 18 h of treatment.